 SALT LAKE CITY, May 24, 2021 GLOBE NEWSWIRE -- Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA. Q2 Solutions provides comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions. Myriad RBM, which specializes in contract research services for the pharmaceutical industry, will be added to the overall Q2 Solutions menu and offerings. 